Phase 1b Study of PTC299 in Relapsed/Refractory Acute Leukemias
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
PTC Therapeutics, Inc
Start Date
January 7, 2020
End Date
January 14, 2025
Administered By
Duke Cancer Institute
Awarded By
PTC Therapeutics, Inc
Start Date
January 7, 2020
End Date
January 14, 2025